|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 15, 12755-12761, April 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Pharmaceutical Chemistry, University of
California, San Francisco, California 94143-0446
Received for publication, December 19, 2001, and in revised form, January 29, 2002
The prosthetic heme group in the CYP4A family of
cytochrome P450 enzymes is covalently attached to an I-helix glutamic
acid residue. This glutamic acid is conserved in the CYP4 family but is
absent in other P450 families. As shown here, the glutamic acid is
linked, presumably via an ester bond, to a hydroxyl group on the heme
5-methyl group. Mutation of the glutamic acid to an alanine in CYP4A1,
CYP4A3, and CYP4A11 suppresses covalent heme binding. In wild-type
CYP4A3 68% of the heme is covalently bound to the heterologously
expressed protein, but in the CYP4A3/E318D mutant, 47% of the heme is
unchanged, 47% is present as noncovalently bound 5-hydroxymethylheme,
and only 6% is covalently bound to the protein. In the CYP4A3/E318Q
mutant, the majority of the heme is unaltered, and <2% is covalently
linked. The proportion of covalently bound heme in the recombinant
CYP4A proteins increases with time under turnover conditions. The
catalytic activity is sensitive in some, but not all, CYP4A enzymes to
the extent of covalent heme binding. Mutations of
Glu318 in CYP4A3 decrease the apparent
kcat values for lauric acid hydroxylation. The
key conclusions are that (a) covalent heme binding occurs via an ester bond to the heme 5-methyl group, (b) covalent
binding of the heme is mediated by an autocatalytic process, and
(c) fatty acid oxidation is sensitive in some CYP4A enzymes
to the presence or absence of the heme covalent link.
It has been known for some time that the prosthetic
heme1 group is covalently
bound to the protein in both the cytochromes c and the
mammalian peroxidases. In the cytochromes c, the heme is
attached to the protein via thioether bonds between the original heme
vinyl groups and two of the cysteine residues (1). In the mammalian
peroxidases, the heme is linked to the protein via two ester bonds
involving aspartate or glutamic acid residues and hydroxyl groups on
two of the original heme methyl groups (2). In addition, in
myeloperoxidase a third covalent link is present between a methionine
sulfur atom and one of the heme vinyl groups (2, 3). Formation of the
covalent bonds between the heme and the protein in the cytochromes
c requires the intervention of several proteins specifically
devoted to that task (4, 5). In contrast, recent work from this
laboratory has demonstrated that the covalent bonds in lactoperoxidase
are formed via an autocatalytic process when the noncovalent
heme-protein complex reacts with H2O2 (6, 7).
Evidence that similar autocatalytic processes mediate covalent
attachment of the heme groups in the eosinophil and thyroid peroxidases
has subsequently been reported (8, 9).
The role of covalent heme attachment in cytochrome c remains
elusive (10), as removal of one or both of the covalent links to the
heme by site-specific mutagenesis has little apparent effect on the
properties of the protein (11). In contrast, recent work has shown that
one covalent link is expendable in lactoperoxidase (7), but activity is
lost when both covalent links are suppressed by site-specific mutations
in lactoperoxidase and myeloperoxidase (7, 12-14).
The CYP4 family of cytochrome P450 enzymes catalyzes the Materials--
Primers were ordered from Invitrogen. Restriction
enzymes and T4 DNA ligase were purchased from New England Biolabs
(Beverly, MA). [14C]lauric acid (55 mCi/mmol) was from
American Radiolabeled Chemicals, Inc. (St. Louis, MO). Purified rat
liver cytochrome b5 was a gift from Lester
Bornheim (University of California, San Francisco). Cytochrome P450
reductase cDNA was expressed and purified as reported previously
(18). Ampicilin, Preparation of the CYP4A3/E318A, E318Q, and E318D
Mutants--
The CYP4A genes were excised from the pCWori/4A plasmid
by digestion with NdeI and SalI restriction
enzymes. The CYP4A genes were then subcloned into the pUC19 vector, and
this plasmid was used for mutagenesis. The QuikChange (Stratagene, La
Jolla, CA) method was used to make the substitutions. The following
primers were used to prepare the mutants. Underlined codons represent the base pair changes that were made to effect the amino acid point
mutations. The bold letter indicates the base change for NaeI, a unique restriction site. For CYP4A3/E318A, the
forward primer was 5'-GAC ACA TTC ATG TTT GCC GGC
CAT GAC ACC GCC AGT G-3', and the reverse primer was 5'-C
ACT GGC GGT GTC ATG GCC GGC AAA CAT GAA TGT
GTC-3'. For CYP4A3/E318D the forward primer was 5'-G GAC ACA TTC ATG
TTT GAC GGT CAT GAC ACC ACA G-3', and the reverse primer
was 5'-C TGT GGT GTC ATG ACC GTC AAA CAT GAA TGT GTC G-3'.
For CYP4A3/E318Q, the forward primer was 5'-G GAC ACA TTC ATG TTT
CAG GGT CAT GAC ACC ACA G-3', and the reverse primer was
5'-C TGT GGT GTC ATG ACC CTG AAA CAT GAA TGT GTC C-3'. For
CYP4A11/E321A, the forward primer was 5'-TTC ATG TTT GCC
GGC CAC GAC ACC AC-3', and the reverse primer was 5'-GT GGT GTC GTG GCC
GGC AAA CAT GAA-3'. The CYP4A3/E318A mutation was confirmed by restriction digestion and sequencing, and the CYP4A3/E318D, CYP4A3/E318Q, and CYP4A11/E321A enzymes were confirmed by sequence analysis. The CYP4A mutant genes were then excised from the pUC19 vector by digestion with NdeI and SalI and were
ligated into the pCWori expression vector using T4 DNA ligase. The
CYP4A1/E320A mutant was described previously (18).
Protein Purification--
As described previously,
the hexahistidine-tagged proteins were expressed in DH5- Spectroscopic Methods--
Reduced CO difference and absolute
spectra were recorded on a Hewlett-Packard 8452 diode array
spectrophotometer. The P450 content was determined using the method of
Omura and Sato (22). Binding data were collected on a Varian Cary 1E
UV/visible dual-beam spectrophotometer. To obtain substrate binding
difference spectra, the fatty acids were dissolved in dimethyl
sulfoxide and titrated into the CYP4A protein solution. The spectral
binding constant Ks was determined from the
hyperbolic plot of the differences in the peak to trough absorbance
change versus the ligand concentration (23).
Measurement of CYP4A Hydroxylation Activity--
CYP4A
HPLC-UV Analysis of CYP4A Proteins--
Purified and desalted
CYP4A mutant proteins were analyzed on a POROS R2 perfusive particle
column (4.6 × 100 mm) from Perceptive Biosystems (Framingham,
MA). The solvent gradient consisted of a mixture of buffer A (0.1%
trifluoroacetic acid in water) and buffer B (0.05% trifluoroacetic
acid in acetonitrile) with a flow rate of 1.5 ml/min. The bound and
unbound heme species were separated with the following protocol of
stepwise linear gradients: 30% buffer B for 3 min, 30-50% buffer B
from 3 to 8 min, 50% buffer B from 8 to 9.5 min, 50-95% buffer B
from 9.5 to 13 min, 95% buffer B from 13 to 18 min, and finally
recycling back to 30% buffer B for 2 min. Under these conditions, the
free heme eluted at 6 min, the more polar heme at 3.3 min, and the
protein-bound heme at around 12.5 min. The heme group and protein were
monitored at 400 and 280 nm, respectively.
Prosthetic Group Characterization--
Desalted CYP4A8 protein
with a high degree of covalently bound heme was digested overnight at
37 °C with Pronase (Sigma) (1 mg/ml) in 50 mM Tris, pH
7.5, buffer. The digested sample was then injected onto the reverse
phase POROS R2 perfusive particle column (4.6 × 100 mm) from
Perceptive Biosystems. Buffer A (water with 0.1% trifluoroacetic acid)
and buffer B (acetonitrile with 0.05% trifluoroacetic acid) were
employed at a flow rate of 1 ml/min. Conditions of the column were 3 min at 27% buffer B, 3-40.5 min from 27-33% Buffer B, then 40.5-43
min from 33-95% buffer B, 43-48 min with 95% buffer B, 48-52 min
from 95-27% buffer B, and then 52-55 min at 27% buffer B. Under
these conditions the 8-hydroxymethylheme standard eluted at 4.6 min,
the 5-monohydroxylated heme at 8.2 min, the monohydroxylated heme from
the CYP4A8 digest at 8.2 min, and free heme at ~19.6 min.
Spectroscopic Characterization of the Mutant Proteins--
The
CYP4A proteins with mutations at the site to which the heme is
covalently attached were expressed in DH5-
All of the mutant enzymes, like their wild-type parents, have a typical
Soret maximum at 450 nm in the ferrous, CO-bound state. However, the
reduced CO difference spectra indicate that the CYP4A3/E318A, CYP4A3/E318D, and CYP4A11/E321A proteins were contaminated by the
presence of denatured cytochrome P450 species absorbing at 420 nm
(Table II). The CYP4A3/E318A mutant contains ~75% of the 420 nm
species, the CYP4A3/E318D mutant ~50%, and the CYP4A11/E321A mutant
~30%. The reduced CO difference spectra of the wild-type proteins
and of the other mutants only contained the species absorbing at 450 nm. In all instances, the quantitative data reported in this manuscript
are based exclusively on the protein with 450 nm absorption maximum.
Analysis of Covalent Heme Binding in the CYP4A
Mutants--
Wild-type CYP4A1, CYP4A3, and CYP4A11 have ~36%, 68%,
and 26%, respectively, of their heme covalently bound to the protein (16). When the indicated glutamic acid in these proteins is mutated to
an alanine, the heme group is no longer covalently bound (Table
III, Fig.
1). In the CYP4A3/E318D mutant, 6% of
the heme is covalently attached, 47% of the heme is monohydroxylated but not covalently bound, and 47% of the heme is unmodified. In the
CYP4A3/E318Q enzyme, virtually all of the heme is unmodified, with less
than 2% of the heme being covalently bound. The percent of covalently
bound heme in the proteins as isolated was fairly constant except for
CYP4A8, for which the percent of covalently bound heme ranged from 40 to 80%.
Heme Site Involved in Binding to Protein--
Earlier mass
spectrometric analyses showed that the covalently bound heme released
by Pronase from the CYP4A proteins is monohydroxylated, but the
location of the hydroxyl group could not be determined. A CYP4A8 sample
with a high percentage of covalently bound heme was selected to
determine the location of the hydroxyl group on the heme. The CYP4A8
protein was digested with Pronase for 20 h to release the
covalently attached heme (Fig. 2). The
sample was then subjected to HPLC chromatography on a POROS column to identify the hydroxylated heme group by direct comparison with authentic samples. Authentic 8-hydroxymethylheme was obtained as
reported previously from phenyldiazene-treated horseradish peroxidase
(19). The 1- and 5-hydroxymethylhemes were obtained from
lactoperoxidase mutants unable to form one of the two covalent bonds to
the heme (7). The 8-hydroxymethylheme eluted at 4.6 min, the
5-hydroxymethylheme at 8.2 min, and unmodified heme at ~19.6 min in
our HPLC system (Fig. 3). The
1-hydroxymethyl derivative eluted at a quite different position. The
monohydroxylated heme species released by digestion of CYP4A8 elutes at
8.2 min, exactly where the 5-hydroxymethyl derivative elutes and at a
position quite distinct from that of the 8- or 1-hydroxymethyl
derivatives. These results, in conjunction with the mass spectrometric
evidence that the heme has one extra oxygen atom and the fact that the absorption spectrum of the heme chromophore is unaltered (16), strongly
suggest that the oxygen is attached to the 5-methyl of the heme as a
hydroxyl moiety.
The noncovalently bound monohydroxylated heme species obtained with the
CYP4A3/E318D mutant also elutes at 8.2 min under the chromatographic
conditions (Fig. 3). The noncovalently bound species is thus the same
as that obtained when the heme is covalently bound, except that the
protein need not be digested to release the derivative.
Autocatalytic Attachment of the Heme--
An increase in the
percentage of covalently bound heme was observed with time when
heterologously expressed CYP4A2, CYP4A11, and CYP4A8 were incubated
under turnover conditions (Fig. 4). CYP4A3 was not used in these experiments because of the high level of
heme already covalently bound in the wild-type protein. A 12% increase
in the covalently bound heme was observed in 20 min for CYP4A2, a 49%
increase in 50 min for CYP4A8, and a 10% increase in 15 min for
CYP4A11. When the proteins were incubated in the presence of all of the
reaction components except NADPH, the percentage of covalently bound
heme did not increase.
Binding Constants--
The binding of imidazole and lauric acid to
the mutant proteins was investigated (Table
IV). The binding constants for imidazole and lauric acid are decreased by 2.3- and 2.7-fold for CYP4A1/E320A relative to wild-type CYP4A1. In CYP4A11/E321A the binding of imidazole
is decreased 6-fold relative to wild-type CYP4A11, but the binding
constants for lauric acid are approximately the same for both proteins.
The CYP4A3/E318D mutation decreases the binding constants for lauric
acid and imidazole by 13- and 28-fold, respectively, as compared with
wild-type CYP4A3. In CYP4A3/E318Q an 8-fold decrease in binding is
observed for both imidazole and lauric acid relative to wild-type
CYP4A3. In the CYP4A3/E318A enzyme a 1.4-fold decrease is observed for
imidazole binding as compared with wild-type CYP4A3.
Kinetics--
The lauric acid hydroxylation activities of the
CYP4A1, CYP4A3, and CYP4A11 mutants were determined (Table III). The
apparent kcat of the CYP4A1/E320A mutant was
3-fold lower than that of wild-type CYP4A1. For the CYP4A3E318D,
-E318Q, and -E318A mutants the apparent lauric acid
kcat values were 6-, 8-, and 20-fold lower,
respectively, than that of wild-type CYP4A3. However, the apparent
kcat value of the CYP4A11/E321A mutant was the
same as that of the wild-type protein. It is perhaps significant that the extent of the changes in the apparent kcat
values roughly parallel the corresponding changes in the lauric acid
binding constants.
Previous investigations have demonstrated that the prosthetic heme
group of several proteins of the CYP4 family is covalently bound to the
protein. Although the studies were carried out primarily with proteins
heterologously expressed either in Escherichia coli (16) or
a baculovirus system (17), the extent of covalent binding was found to
be as high or higher in CYP4A1 isolated from rat liver (16). Covalent
binding is thus not an artifact of heterologous expression. The site of
covalent attachment was shown by proteolytic experiments to be a
conserved glutamic acid residue in the I-helix (16). However, the
nature of the covalent link and the site on the heme involved in
covalent attachment were not determined.
The present studies confirm the role of the glutamic acid, establish
that it is the unique site of attachment of the heme to the protein,
and demonstrate that the link to the heme involves a hydroxyl group on
the 5-methyl of the heme (Fig. 5). Thus,
mutation of the glutamic acid to an alanine in CYP4A1, CYP4A3, and
CYP4A11 yields proteins with normal Fe2+-CO absorption
spectra at 450 nm but in which covalent binding of the heme is
completely suppressed (Fig. 1). Furthermore, replacement of the
glutamic acid by a glutamine, a substitution that preserves the bulk of
the side chain but eliminates the carboxylic acid terminus, yields a
protein that again absorbs at 450 nm in the Fe2+-CO state
but in which no more than a trace of the heme is covalently bound (Fig.
1). It is clear from these experiments that the carboxylic acid moiety
of the glutamic acid is critical for the covalent attachment
process.
Mutation of the indicated glutamic acid to an alanine in the CYP4A
proteins results in a blue shift of the Soret band (Table II). A blue
shift is also observed when the carboxylic acid residues that
covalently bind to the heme are mutated in myeloperoxidase (Glu242 Pronase digestion of CYP4A8, using a sample with a high degree of
covalent heme binding, led to isolation of the modified prosthetic
group. Previous mass spectrometric analysis of this prosthetic group
established that its mass corresponded to that of heme plus an oxygen
atom (16). As the absorption spectrum of the isolated heme was
essentially the same as that of heme itself, the modified heme group
was tentatively identified as a monohydroxylated heme. The site of
hydroxylation could not be determined from the mass spectrometric data,
but has been identified in the present experiments by comparison of the
prosthetic group released proteolytically from the protein with
authentic samples of the 1-hydroxymethyl-, 5-hydroxymethyl-, and
8-hydroxymethylheme derivatives (Fig. 3). The isolated prosthetic group
has exactly the same retention time as 5-hydroxymethyl and a retention
time well resolved from those of the 1- and 8-hydroxymethyl standards. In view of this chromatographic comparison and the earlier mass spectrometric and spectroscopic evidence (16), it is clear that the
heme is linked to the protein via a hydroxyl group on the 5-methyl of
the heme. It is virtually certain, therefore, that the heme-protein
link is an ester bond involving the carboxylic moiety of the glutamic
acid and the hydroxyl on the heme (Fig. 5).
When Glu318 in CYP4A3 is replaced by an
aspartic acid, the side chain is shortened by one methylene group. This
mutation greatly decreases covalent binding of the heme but, unlike the
alanine mutation, does not completely suppress it. Only 6% of the heme is covalently bound, in contrast to the 68% observed with the wild-type protein. As a consequence, 47% of the prosthetic group in
the CYP4A3/E318D mutant is unmodified heme. The most interesting finding, however, is that 47% of the prosthetic group is present as
5-hydroxymethylheme that is not covalently bound (Fig. 3)! HPLC analysis shows that the site of the hydroxyl moiety is the same in
the covalently bound and noncovalently bound but modified heme group.
The decrease in covalent binding due to the aspartate substitution
reinforces the conclusion that the glutamic acid carboxylic acid group
is required for covalent bond formation. More importantly, the finding
that the substitution produces a substantial yield of modified but
noncovalently bound prosthetic group considerably clarifies the
mechanism of covalent bond formation (see below).
A major finding is that the extent of covalent binding of the heme to
the protein increases with time when the recombinant enzyme is
incubated under catalytic turnover conditions. Increases of 12%, 49%,
and 10% were observed with CYP4A2, CYP4A8, and CYP4A11, respectively.
These increases were absolutely dependent on catalytic turnover, as
they did not occur when NADPH was omitted from the incubation system.
Larger increases in covalent binding were difficult to observe, because
the heme was already partially covalently bound, limiting the possible
increase, and because incubation under turnover conditions also leads
with time to inactivation of the protein. Nevertheless, the results
clearly indicate that the heme is covalently bound to the protein
through an autocatalytic process. Autocatalytic formation of an ester
bond between the 5-methyl of the heme and the glutamic acid carboxyl
moiety is likely to involve trapping of a heme 5-methyl carbocation by
the carboxylic acid group. Support for this mechanism is provided by
the finding that substantial amounts of noncovalently bound 5-hydroxymethylheme are formed when the glutamic acid is replaced by an
aspartate group (Fig. 3). Shortening the chain that tethers the
carboxylic acid group to the protein backbone apparently decreases its
ability to compete with water for trapping of the carbocation, resulting in covalent binding of the prosthetic group when the carboxylic acid group is successful, but formation of noncovalently bound 5-hydroxymethylheme when the carbocation is trapped by a water molecule in the enlarged active site. Radical and acid-base mechanisms can be written for formation of the 5-methyl carbocation, but the available evidence does not allow a distinction to be made
between the possible routes to this critical intermediate.
The autocatalytic mechanism demonstrated here for covalent attachment
of the heme in CYP4 enzymes resembles that for covalent linking of the
prosthetic group to the protein in the mammalian peroxidases (6, 7).
There are two obvious differences, however. Covalent binding of the
heme to the protein in lactoperoxidase involves two rather than one
ester bond, one between Asp225 and the 5-methyl group and
the other between Glu375 and the 1-methyl group (25). A
second significant difference is that autocatalytic cross-linking of
the heme in the mammalian peroxidases is promoted by reaction with
H2O2, whereas the reaction in the CYP4A enzymes
involves reaction with oxygen and NADPH-cytochrome P450 reductase. It
is nevertheless likely that the basic mechanism will be the same in
both systems, i.e. activation via a ferryl species of the
methyl group to a carbocationic intermediate that is subsequently
trapped by the appropriate carboxylic acid side chain (Fig. 5).
No crystal structure is available of a CYP4 protein, but a state of the
art CYP4A11 homology model has been constructed by Chang and Loew (26).
Although it is necessary to keep in mind the shortcomings of P450
homology models, the carboxylic acid side chain of Glu321
in the CYP4A11 model is closer by 1-2 Å to the 5- and 8-methyl groups
of the heme than the 1- and 3-methyls. In the model, the 5- and
8-methyl groups are both ~7.7 Å from the critical glutamic acid
residue. The model is thus consistent with formation of a covalent link
to either the 5- or 8-methyl group, but is not sufficiently accurate to
distinguish between these two positions.
Does covalent heme binding influence the catalytic function of CYP4
enzymes? The apparent kcat for lauric acid
hydroxylation decreases from 150 to 54 min It must be kept in mind, of course, that covalent binding
of the heme group may influence other properties of the CYP4A enzymes than their catalytic activity with lauric acid. A BLAST search of the
protein data bases for the glutamic acid residue and its conserved
context (EGHDTT) indicates that it is highly (but not
absolutely) conserved in the CYP4 family (Table I). This high degree of
conservation of the glutamic group suggests that covalent heme binding
may be important in other aspects of CYP4A function, particularly those
that are relevant to its in vivo function. However, no
conclusions can yet be made relative to alternative functions of
covalent heme binding in the CYP4A family.
In summary, we have provided evidence that the covalent link to the
heme in the CYP4A proteins is an ester bond between a glutamic acid
residue and a hydroxyl group on the 5-methyl of the heme, that the
covalent bond is formed by an autocatalytic process probably involving
trapping of a carbocationic intermediate by the glutamic acid, and that
covalent binding is important for lauric acid oxidation in some but not
all CYP4A enzymes.
We thank Christophe Colas for the authentic
1-, 5-, and 8-hydroxymethylheme samples.
*
This work was supported by National Institutes of Health
Grant GM25515.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, January 30, 2002, DOI 10.1074/jbc.M112155200
2
L. A. LeBrun, F. Xu, D. L. Kroetz, and
P. R. Ortiz de Montellano, unpublished results.
The abbreviations used are:
heme, iron
protoporphyrin IX regardless of oxidation and ligation state;
CYP, cytochrome P450;
HPLC, high pressure liquid chromatography.
Autocatalytic Mechanism and Consequences of Covalent Heme
Attachment in the Cytochrome P4504A Family*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
and
-1
hydroxylation of fatty acids (15). We recently established that the
heme is covalently bound to the protein in the CYP4A family of proteins
(16), and subsequent work has extended the evidence for heme covalent
binding to members of the CYP4B and CYP4F families
(17).2 The heme is bound to
the CYP4A proteins via a conserved glutamic acid residue on the I-helix
of the protein (16). BLAST searches of protein data banks show that the
amino acid context of this glutamic acid, EGHDTT, is highly
conserved in the CYP4A family (Table I).
This conserved sequence is present in species that range from
Drosophila to humans. The CYP4 family is one of the most
ancient in the P450 superfamily, having originated over 1 billion years
ago before the divergence of invertebrates and vertebrates (15). None
of the known P450 families outside of the CYP4 family has a glutamic
acid residue at the indicated position. In this paper, we identify the
site on the heme that is involved in covalent bond formation,
demonstrate that heme binding is the result of an autocatalytic
process, and explore the consequences of covalent heme attachment to
the protein in the P450 system.
The EGHDTT sequence in the I-helix is highly conserved in the CYP4
family
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-aminolevulinic acid, glycerol, lysozyme,
dilauroylphosphatidylcholine, glutathione, catalase, heme,
NADPH, trifluoroacetic acid, and lauric acid were obtained from
Sigma-Aldrich. Emulgen 913 was a gift from KAO Chemicals (Tokyo,
Japan). Acetonitrile (HPLC-grade) was purchased from Fisher Scientific.
The 1-, 5-, and 8-hydroxymethylheme standards were obtained and
purified as reported elsewhere (7, 19). The CYP4A1, -4A2, -4A3, -4A8,
and -4A11 plasmids were constructed as reported previously (20).
cells,
purified on a Ni2+-nitrilotriacetic acid-agarose
column from Qiagen (Chatsworth, CA), and desalted on a P10 column from
Amersham Biosciences (Solna, Sweden) (20).
-hydroxylation was measured by mixing together 10 µg of
dilauroylphosphatidylcholine, 250 pmol of cytochrome P450 reductase, 25 pmol of cytochrome b5, 5 µg of catalase, and
picomole concentrations of CYP4A protein. This mixture was incubated
for 10 min at room temperature, and then 50 mM Tris, pH
7.5, buffer containing 250 mM NaCl and 10% glycerol was
added to a final volume of 490 µl. Finally, 5 µl of a 10 mM 5:1 mixture of unlabeled to 14C-labeled
fatty acid that produced a final concentration of 100 µM
was added. The samples were incubated for 2 min at 37 °C, and then
the reaction was started by adding NADPH to a final concentration of 2 mM. The reaction was carried out from 0 to 30 min at
37 °C. The reactions were stopped by removing 50-µl aliquots at
the indicated time periods and quenching them by the adding 100 µl of
94:6 (v/v) acetonitrile/acetic acid. The samples were analyzed by HPLC
as described previously (18). The autocatalytic attachment of
the heme was monitored by mixing the protein and other components together as described above. In these experiments unlabeled lauric acid
was used, and the samples were analyzed by HPLC. The reaction samples
were removed from 37 °C incubations at various time points and
injected directly onto the POROS column to determine the percentage of
bound and free heme (described below).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
cells and purified on a
Ni2+-nitrilotriacetic acid-agarose column. In the
CYP4A1/E320A, CYP4A3/E318A, and CYP4A11/E321A mutants, the Soret bands
are blue shifted relative to those of the corresponding wild-type
proteins (Table II). The absorption
maximum of the CYP4A1/E320A mutant at 390 nm indicates that the protein
is in a high rather than low spin state. The Soret bands of the
CYP4A3/E318A and CYP4A11/E321A mutants at 406 nm are also lower than
those of the corresponding wild-type proteins at 420 and 417 nm,
respectively, but are not as low as that of the CYP4A1/E320A mutant. If
the mutation introduces a shorter carboxylic acid side chain, as in the
CYP4A3/E318D, the Soret band remains unchanged at 420 nm. The position
of the Soret band thus appears to be related to the size and/or
polarity of the side chain, as a normal low spin protein is obtained
with the large electronegative carboxylic acid side chains of glutamic and aspartic acid, whereas a high spin state is observed when the side
chain is replaced by the smaller and neutral alanine methyl group.
The finding that the CYP4A3/E318Q Soret band is at 415 nm suggests that
it is the size of the side chain, rather than the presence of a
negative carboxylic acid group, that is most important in determining
the position of the absorption maximum.
Absorption maxima of CYP4A1, CYP4A3, and CYP4A11 and their mutants in
the Fe3+ and Fe2+-CO states
The percentage of covalently bound heme and the kinetic constants for
lauric acid hydroxylation for wild-type and mutant CYP4A enzymes

View larger version (14K):
[in a new window]
Fig. 1.
HPLC analysis of covalent heme attachment in
CYP4A3 mutants. Desalted protein samples were injected onto a
POROS R2 perfusive column, and the heme chromophore was monitored at
400 nm: A, heme standard; B, monohydroxylated
heme; C, wild-type CYP4A3; D, CYP4A3/E318A;
E, CYP4A3/E318D; and F, CYP4A3/E318Q. Unmodified
heme elutes at 6 min, monohydroxylated heme at 3.3 min, and
protein-bound heme around 12.5 min.

View larger version (17K):
[in a new window]
Fig. 2.
HPLC analysis of the CYP4A8 protein before
and after Pronase digestion. A desalted CYP4A8 sample was injected
onto the HPLC and monitored at 400 nm (A) and 280 nm
(B). The unmodified heme elutes at 6 min and the
protein-bound heme at 12.5 min. In the CYP4A8 protein the majority of
the heme is covalently bound. The CYP4A8 sample after overnight
digestion with Pronase was similarly subjected to HPLC analysis with
monitoring at 400 nm (C) and 280 nm (D). All of
the covalently bound heme was released from the protein. The polar heme
that is released elutes at 3.3 min.

View larger version (19K):
[in a new window]
Fig. 3.
HPLC analysis of the polar heme species with
the detector set at 400 nm. Samples were injected onto the POROS
column and separated as indicated under "Materials and Methods."
The reduced CO spectra of the CYP4A8 sample used for this experiment
contained over 85% of the protein species absorbing at 450 nm:
A, 8-hydroxymethylheme standard; B, unmodified
heme standard; C, 5-hydroxymethylheme standard;
D, digested CYP4A8 sample; and E, desalted
CYP4A3/E318D protein. 8-Hydroxymethylheme elutes at 4.6 min,
5-hydroxymethylheme at 8.2 min, and unmodified heme around 19.6 min.

View larger version (17K):
[in a new window]
Fig. 4.
Autocatalytic heme attachment in CYP4A
proteins. The percentage of heme bound to the protein increases
under catalytic conditions in a time-dependent manner with
CYP4A2 (
), CYP4A8 (
), and CYP4A11 (
). In the absence of NADPH
the percentage of protein-bound heme remains unchanged. The reduced CO
spectra for the CYP4A8 sample used for this experiment contained a
60:40 mixture of 420 and 450 nm species. The change in the percent of
covalently bound heme was calculated for the active 450 nm-absorbing
species only.
Spectroscopic binding constants (Ks) for wild-type and
mutant CYP4A proteins
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (10K):
[in a new window]
Fig. 5.
Site of covalent binding of the heme to the
protein and proposed carbocation-trapping mechanism for formation of
the ester bond between the protein and heme group. In the
CYP4A3/E318D mutant, trapping of the carbocation by water competes with
trapping by the glutamic acid group.
Gln and Asp94
Asn) (24) and
lactoperoxidase (Glu375
Gln) (12). These mutations
clearly affect the spectral properties of the protein. However, when
the mutants retain a carboxylic acid at the site of attachment, as in
CYP4A3/E318D (Table II) or a lactoperoxidase mutant (7), the Soret band
is not shifted. The differences observed with the neutral substitutions
could reflect the presence versus absence of the covalent
bond, but could simply be due to differences in the active site
polarity or water occupancy caused by the mutations.
1 when
Glu320 is mutated to an alanine in CYP4A1, and from 77 to
3.4 min
1 when Glu318 is similarly mutated in
CYP4A3 (Table III). However, mutating Glu321 to an alanine
in CYP4A11 does not alter the lauric acid hydroxylation activity. These
results clearly demonstrate that covalent heme binding is important,
but not absolutely required, for the catalytic activity of CYP4A1 and
particularly CYP4A3. In the case of CYP4A11, covalent heme binding is
not a detectable determinant of the rate of lauric acid hydroxylation.
Analysis of the binding of imidazole and lauric acid to the mutant and
wild-type proteins reinforces these conclusions. Thus, the binding of
imidazole is significantly decreased in all the mutants relative to the
wild-type proteins (Table IV). More interestingly, the binding of
lauric acid is also decreased in the CYP4A1 and CYP4A3, but not CYP4A11
mutants. The fact that both the wild-type and mutant proteins consist
of mixtures of covalently and noncovalently bound heme complicates the
quantitative interpretation of these ligand binding alterations, but
the qualitative conclusion that the CYP4A1 and CYP4A3 protein active
sites are more sensitive to covalent binding of the heme than the
CYP4A11 protein appears warranted.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of
Pharmaceutical Chemistry, University of California, San Francisco,
School of Pharmacy, S-926, 513 Parnassus Ave., San Francisco, CA
94143-0446. Fax: 415-502-4728; E-mail:
ortiz@cgl.ucsf.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Moore, G. R.,
and Pettigrew, G. W.
(1990)
in
Cytochromes c: Evolutionary, Structural, and Physiochemical Aspects
(Rich, A., ed)
, Springer-Verlag, Berlin
2.
Fiedler, T. J.,
Davey, C. A.,
and Fenna, R. E.
(2000)
J. Biol. Chem.
275,
11964-11971 3.
Fenna, R.,
Zeng, J.,
and Davey, C.
(1995)
Arch. Biochem. Biophys.
316,
653-656[CrossRef][Medline]
[Order article via Infotrieve] 4.
Page, M. D.,
Sambongi, Y.,
and Ferguson, S. J.
(1998)
Trends Biochem. Sci.
23,
103-108[CrossRef][Medline]
[Order article via Infotrieve] 5.
Thöny-Meyer, L.
(2000)
Biochim. Biophys. Acta
1459,
316-324[Medline]
[Order article via Infotrieve] 6.
DePillis, G. D.,
Ozaki, S,
Kuo, J. M.,
Maltby, D. A.,
and Ortiz de Montellano, P. R.
(1997)
J. Biol. Chem.
272,
8857-8860 7.
Colas, C.,
Kuo, J. M.,
and Ortiz de Montellano, P. R.
(2002)
J. Biol. Chem.
277,
7191-7200 8.
Fayadat, L.,
Niccoli-Sire, P.,
Lanet, J.,
and Franc, J. L.
(1999)
J. Biol. Chem.
274,
10533-10538 9.
Oxvig, C.,
Thomsen, A. R.,
Overgaard, M. T.,
Sorensen, E. S.,
Hojrup, P.,
Bjerrum, M. J.,
Gleich, G. J.,
and Sottrup-Jensen, L.
(1999)
J. Biol. Chem.
274,
16953-16958 10.
Barker, P. D.,
and Ferguson, S. J.
(1999)
Structure (Lond.)
7,
R281-R290[Medline]
[Order article via Infotrieve] 11.
Tomlinson, E. J.,
and Ferguson, S. J.
(2000)
J. Biol. Chem.
275,
32530-32534 12.
Suriano, G.,
Watanabe, S.,
Ghibaudi, E. M.,
Bollen, A.,
Ferrari, R. P.,
and Moguilevsky, N.
(2001)
Bioorg. Med. Chem. Lett.
11,
2827-2831[CrossRef][Medline]
[Order article via Infotrieve] 13.
Kooter, I. M.,
Noguilevsky, N.,
Bollen, A.,
Sijtsema, N. M.,
Otto, S.,
Dekker, H. L.,
and Wever, R.
(1999)
Eur. J. Biochem.
264,
211-217[Medline]
[Order article via Infotrieve] 14.
Kooter, I. M.,
Moguilevsky, N.,
Bollen, A.,
van der Veen, L. A.,
Otto, C.,
Dekker, H. L.,
and Wever, R.
(1999)
J. Biol. Chem.
274,
26794-26802 15.
Simpson, A. E. C. M.
(1997)
Gen. Pharmacol.
28,
351-359[Medline]
[Order article via Infotrieve] 16.
Hoch, U.,
and Ortiz de Montellano, P. R.
(2001)
J. Biol. Chem.
276,
11339-11346 17.
Henne, K. R.,
Kunze, K. L.,
Zheng, Y. M.,
Christmas, P.,
Soberman, R. J.,
and Rettie, A. E.
(2001)
Biochemistry
40,
12925-12931[CrossRef][Medline]
[Order article via Infotrieve] 18.
Dierks, E. A.,
Davis, S. C.,
and Ortiz de Montellano, P. R.
(1998)
Biochemistry
37,
1839-1847[CrossRef][Medline]
[Order article via Infotrieve] 19.
Ator, M.,
and Ortiz de Montellano, P. R.
(1987)
J. Biol. Chem.
262,
1542-1551 20.
Hoch, U.,
Zhang, Z. P.,
Kroetz, D. L.,
and Ortiz de Montellano, P. R.
(2000)
Arch. Biochem. Biophys.
373,
63-71[CrossRef][Medline]
[Order article via Infotrieve] 21.
Dierks, E. A.,
Zhang, A.,
Johnson, E. F.,
and Ortiz de Montellano, P. R.
(1998)
J. Biol. Chem.
273,
23055-23061 22.
Omura, T.,
and Sato, R.
(1964)
J. Biol. Chem.
239,
2370-2378 23.
Orrenius, S.,
Wilson, B. J.,
von Bahr, C.,
and Schenkman, J. B.
(1972)
in
Biological Hydroxylation Mechanisms: Biochemical Society Symposium
(Boyd, G. S.
, and Smellie, R. M. S., eds), Vol. 34
, pp. 55-77, Academic Press, New York
24.
Jacquet, A.,
Garcia-Quintana, L.,
Deleersnyder, V.,
Fenna, R.,
Bollen, A.,
and Moguilevsky, N.
(1994)
Biochem. Biophys. Res. Commun.
202,
73-81[CrossRef][Medline]
[Order article via Infotrieve] 25.
Rae, T. D.,
and Goff, H. M.
(1998)
J. Biol. Chem.
273,
27968-27977 26.
Chang, Y. T.,
and Loew, G. H.
(1999)
Proteins
34,
403-415[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Fer, L. Corcos, Y. Dreano, E. Plee-Gautier, J.-P. Salaun, F. Berthou, and Y. Amet Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism J. Lipid Res., November 1, 2008; 49(11): 2379 - 2389. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Colas and P. R. O. de Montellano Horseradish Peroxidase Mutants That Autocatalytically Modify Their Prosthetic Heme Group: INSIGHTS INTO MAMMALIAN PEROXIDASE HEME-PROTEIN COVALENT BONDS J. Biol. Chem., June 4, 2004; 279(23): 24131 - 24140. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Girvan, K. R. Marshall, R. J. Lawson, D. Leys, M. G. Joyce, J. Clarkson, W. E. Smith, M. R. Cheesman, and A. W. Munro Flavocytochrome P450 BM3 Mutant A264E Undergoes Substrate-dependent Formation of a Novel Heme Iron Ligand Set J. Biol. Chem., May 28, 2004; 279(22): 23274 - 23286. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Lardinois and P. R. O. de Montellano Intra- and Intermolecular Transfers of Protein Radicals in the Reactions of Sperm Whale Myoglobin with Hydrogen Peroxide J. Biol. Chem., September 19, 2003; 278(38): 36214 - 36226. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Carr, S. Ramakanth, G. A. Dannan, and G. S. Yost Characterization of Pulmonary CYP4B2, Specific Catalyst of Methyl Oxidation of 3-Methylindole Mol. Pharmacol., May 1, 2003; 63(5): 1137 - 1147. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |